Verastem, Inc.
VSTMVerastem, Inc. (VSTM) is a biotechnology company focused on developing and commercializing medicines for cancer treatment. The company emphasizes targeting cancer stem cells to improve therapy outcomes, with a portfolio that includes drugs aimed at Kuren and other oncology indications. Founded in 2010, Verastem aims to advance innovative approaches to solid tumor and hematologic cancers.
Company News
The KRAS inhibitors market is projected to grow at a 35% CAGR from 2025-2034, driven by rising cancer incidence and a robust pipeline of targeted therapies for KRAS mutations across multiple cancer types.
Despite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.
The global cancer market is projected to surpass $900 billion by 2034, driven by advancements in cancer treatments from biotech companies like Oncolytics Biotech, Exelixis, Cardiff Oncology, ALX Oncology, and Verastem.
Enphase Energy reported mixed Q2 results, leading to a rise in its stock price. Several other companies saw significant pre-market movements, both positive and negative, due to various news and earnings reports.
The Portnoy Law Firm has initiated an investigation into Verastem, Inc. (NASDAQ: VSTM) for potential securities fraud after the company disclosed serious adverse events in a clinical trial, causing a significant drop in its stock price.
